1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

作者：B.T. Li, David Planchard, Kōichi Goto, Egbert Frederik Smit, J. De Langen, Yasushi Goto, Kiichiro Ninomiya, Toshio Kubo, Maurice Pérol, Enriqueta Felip, H. Hayashi, Kazuhiko Nakagawa, Junichi Shimizu, Misako Nagasaka, Kaline Pereira, Ayumi Taguchi, Ahmed Ali, Maha Karnoub, Rie Yonemochi, Pasi Antero Janne · 发表于：Annals of Oncology · 年份：2023 · DOI：10.1016/j.annonc.2023.09.2354 · 被引用次数：38 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Research Studies、HER2/EGFR in Cancer Research